This phase 1b trial is evaluating the effectiveness of combining three targeted therapies (palbociclib, letrozole and venetoclax) to treat patients with ER and BCL-2 positive locally advanced or metastatic breast cancer.
This trial is treating patients with breast cancer.
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
Patients eligible to participate in this trial will receive a fixed dose of letrozole, which will remain constant throughout the trial. Patients will also receive increasing doses of palbociclib and venetoclax, which will be adjusted according to the results.
Recruiting Hospitals Read More